Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium
Oncolytics Biotech Inc. (NASDAQ: ONCY) has announced the upcoming presentation of two significant data sets at the 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco. The presentations will showcase pelareorep's potential in treating gastrointestinal cancers, specifically focusing on pancreatic and anal cancers.
The first abstract (#6) will present preliminary safety and tumor response results for relapsed anal carcinoma patients treated with pelareorep and atezolizumab. The second abstract (#730) will discuss results from the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, and atezolizumab.
According to Dr. Tom Heineman, Chief Medical Officer, pelareorep works by engaging patients' immune systems to enhance the effectiveness of chemotherapies and checkpoint inhibitors, potentially improving survival rates in these challenging cancers.
Oncolytics Biotech Inc. (NASDAQ: ONCY) ha annunciato la prossima presentazione di due importanti set di dati al 2025 ASCO Gastrointestinal Cancers Symposium a San Francisco. Le presentazioni metteranno in evidenza il potenziale di pelareorep nel trattamento dei tumori gastrointestinali, concentrandosi in particolare sui tumori del pancreas e dell'ano.
Il primo abstract (#6) presenterà i risultati preliminari di sicurezza e risposta tumorale per pazienti con carcinoma anale recidivante trattati con pelareorep e atezolizumab. Il secondo abstract (#730) discuterà i risultati del run-in di sicurezza per pazienti con adenocarcinoma duttale pancreatico metastatico in prima linea trattati con pelareorep, FOLFIRINOX modificato e atezolizumab.
Secondo il Dr. Tom Heineman, Direttore Medico, pelareorep agisce coinvolgendo i sistemi immunitari dei pazienti per migliorare l'efficacia delle chemioterapie e degli inibitori dei checkpoint, potenzialmente migliorando i tassi di sopravvivenza in questi tumori difficili.
Oncolytics Biotech Inc. (NASDAQ: ONCY) ha anunciado la próxima presentación de dos conjuntos de datos significativos en el 2025 ASCO Gastrointestinal Cancers Symposium en San Francisco. Las presentaciones destacarán el potencial de pelareorep en el tratamiento de los cánceres gastrointestinales, centrándose específicamente en los cánceres de páncreas y anal.
El primer resumen (#6) presentará resultados preliminares de seguridad y respuesta tumoral para pacientes con carcinoma anal recidivante tratados con pelareorep y atezolizumab. El segundo resumen (#730) discutirá los resultados del run-in de seguridad para pacientes con adenocarcinoma ductal pancreático metastásico en primera línea tratados con pelareorep, FOLFIRINOX modificado y atezolizumab.
Según el Dr. Tom Heineman, Director Médico, pelareorep funciona al involucrar los sistemas inmunológicos de los pacientes para mejorar la efectividad de las quimioterapias e inhibidores de puntos de control, lo que potencialmente mejora las tasas de supervivencia en estos cánceres desafiantes.
Oncolytics Biotech Inc. (NASDAQ: ONCY)는 샌프란시스코에서 열리는 2025 ASCO Gastrointestinal Cancers Symposium에서 두 가지 중요한 데이터 세트를 발표할 예정이라고 발표했습니다. 이 발표에서는 pelareorep의 잠재력을 위암을 치료하는 데 중점을 두고, 특히 췌장암 및 항문암에 대해 설명할 것입니다.
첫 번째 초록(#6)에서는 pelareorep와 atezolizumab으로 치료받은 재발성 항문암 환자에 대한 안전성과 종양 반응의 초기 결과를 발표합니다. 두 번째 초록(#730)에서는 pelareorep, 수정된 FOLFIRINOX 및 atezolizumab으로 치료받은 1차 전이성 췌장 ductal adenocarcinoma 환자에 대한 안전성 런인 결과를 논의할 것입니다.
Tom Heineman 박사, 최고 의학 책임자에 따르면, pelareorep는 환자의 면역 시스템을 활성화하여 화학요법 및 체크포인트 억제제의 효과를 높이며, 이러한 어려운 암에서 생존율을 개선할 잠재력이 있습니다.
Oncolytics Biotech Inc. (NASDAQ: ONCY) a annoncé la prochaine présentation de deux ensembles de données significatifs lors du 2025 ASCO Gastrointestinal Cancers Symposium à San Francisco. Les présentations mettront en lumière le potentiel de pelareorep dans le traitement des cancers gastro-intestinaux, en se concentrant spécifiquement sur les cancers du pancréas et de l'anus.
Le premier résumé (#6) présentera des résultats préliminaires de sécurité et de réponse tumorale pour les patients atteints de carcinome anal récurrent traités avec pelareorep et atezolizumab. Le deuxième résumé (#730) discutera des résultats des essais de sécurité pour les patients atteints d'adénocarcinome ductal pancréatique métastatique en première ligne traités avec pelareorep, FOLFIRINOX modifié et atezolizumab.
Selon le Dr. Tom Heineman, directeur médical, pelareorep agit en engageant les systèmes immunitaires des patients pour améliorer l'efficacité des chimiothérapies et des inhibiteurs de points de contrôle, ce qui pourrait potentiellement améliorer les taux de survie dans ces cancers difficiles.
Oncolytics Biotech Inc. (NASDAQ: ONCY) hat die bevorstehende Präsentation von zwei bedeutenden Datensätzen beim 2025 ASCO Gastrointestinal Cancers Symposium in San Francisco angekündigt. Die Präsentationen werden das Potenzial von pelareorep bei der Behandlung gastrointestinaler Krebsarten hervorheben, insbesondere bei Bauchspeicheldrüsen- und Analkrebs.
Das erste Abstract (#6) wird vorläufige Sicherheits- und Tumoransprechdaten für Patienten mit rezidivierendem Analkarzinom präsentieren, die mit pelareorep und Atezolizumab behandelt wurden. Das zweite Abstract (#730) wird die Ergebnisse aus dem Sicherheitsrundlauf für Patienten mit metastasiertem duktalem Adenokarzinom der Bauchspeicheldrüse in erster Linie behandeln, die mit pelareorep, modifiziertem FOLFIRINOX und Atezolizumab behandelt wurden.
Laut Dr. Tom Heineman, Chief Medical Officer, funktioniert pelareorep, indem es die Immunsysteme der Patienten aktiviert, um die Wirksamkeit von Chemotherapien und Checkpoint-Inhibitoren zu erhöhen, was potenziell die Überlebensraten bei diesen schwierigen Krebserkrankungen verbessern könnte.
- None.
- None.
SAN DIEGO and
Tom Heineman, M.D., Ph.D., Oncolytics' Chief Medical Officer, said, "We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer. Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devastating diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients."
Abstract Number: 6
Title: GOBLET platform study: Preliminary safety and tumor response results for the relapsed anal carcinoma cohort in patients treated with pelareorep and atezolizumab.
Presentation Type: Poster
Session Title: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date and Time: January 25, 2025, 7:00 - 7:55 a.m. PT
Abstract Number: 730
Title: GOBLET study: Results of the safety run-in for first-line metastatic pancreatic ductal adenocarcinoma (PDAC) patients treated with pelareorep + modified FOLFIRINOX +/- atezolizumab.
Presentation Type: Poster
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Session Date and Time: January 24, 2025, 11:30 a.m. – 1:00 p.m. PT
Abstracts will be published on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our belief that there are multiple clinical and regulatory options for bringing pelareorep to patients; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. We may incur expenses or delays relating to events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and
Company Contact Jon Patton Director of IR & Communication jpatton@oncolytics.ca | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 tim@lifesciadvisors.com |
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-present-promising-pelareorep-data-in-pancreatic-and-anal-cancers-at-asco-gi-symposium-302334441.html
SOURCE Oncolytics Biotech® Inc.
FAQ
What are the two types of cancer being studied with pelareorep (ONCY) in the ASCO GI Symposium presentations?
When and where will Oncolytics Biotech (ONCY) present their pelareorep data at ASCO GI 2025?
How does pelareorep work in treating gastrointestinal cancers according to ONCY's research?
What is the treatment combination being studied for pancreatic cancer in ONCY's GOBLET study?
When will the ASCO GI Symposium abstracts for ONCY's pelareorep studies be published?
